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STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
RELATED APPLICATIONS
This application is a continuation-in-part of U.S. appli-
cation Ser. No. 09/909,122 filed Jul. 19, 2001 which claims
the benefit of U.S. Provisional Application Ser. No. 60/219,
300, filed Jul. 19, 2000, the entire teachings of which are
incorporated herein by reference.
GOVERNMENT SUPPORT
The invention was supported, in wholeor in part, by grant
1 R43 AR45508-01 and 2 R44 AR45508-02 from the
National Institutes of Health. The Government has certain
rights in the invention.
BACKGROUND OF THE INVENTION
Mammalian bonetissue has a remarkableability to regen-
erate and thereby repair injuries and other defects. For
example, bone growth is generally sufficient to bring about
full recovery from most simple and hairline fractures.
Unfortunately, however, there are many injuries, defects or
conditions where bone growth is inadequate to achieve an
acceptable outcome. For example, bone regeneration gen-
erally does not occur throughout large voids or spaces.
Therefore, fractures cannot heal unless the pieces are in
close proximity. If a significant amount of bone tissue was
lost as a result of the injury, the healing process may be
incomplete, resulting in undesirable cosmetic and/or
mechanical outcomes. Thisis often the case with non-union
fractures or with bone injuries resulting from massive
trauma. Tissue growth is also generally inadequate in voids
and segmental gaps in bone caused, for example, by surgical
removal of tumors or cysts. In other instances, it may be
desirable to stimulate bone growth where bone is not nor-
mally found, 1.e., ectopically. Spine fusion to relieve lower
back pain where two or more vertebrae are induced to fuse
is one example of desirable ectopic bone formation.
Currently, such gaps or segmental defects require bone
grafts for successful repair or gap filling. The development
of effective bone graft substitutes would eliminate the need
to harvest bone from a second surgical site for a graft
procedure, thereby significantly reducing the discomfort
experienced by the patient and risk of donorsite healing
complications.
Compounds which stimulate or induce bone growth at
sites where such growth would not normally occur if left
untreated are said to be “osteoinductive”. An osteoinductive
compound would have great value as a drug to treat the
conditions described above. A number of osteoinductive
proteins have been identified, isolated and expressed using
recombinant technology. Examples include the bone mor-
phogenic proteins (BMPs) disclosed in U-S. Pat. No. 5,902,
705 and WO 95/16035. However, the use of recombinant
proteins as therapeutic agents generally has a number of
drawbacks, including the cost of manufacture, in vivo bio-
degradation and short shelf lives. Consequently, scientists
are continuing to search for new osteoinductive agents
which do not have the aforementioned shortcomings.
SUMMARYOF THE INVENTION
It has now been found that compounds whichactivate the
non-proteolytic thrombin receptor are osteoinductive. For
example, the compound TP508, an agonist of the non-
proteolytic thrombin receptor, stimulates bone growth in
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segmental critical size defects created in the ulna of male
New Zealand rabbits (Example 2). As shown by x-ray and
confirmed by histology and mechanical testing, there was a
significant increase in bone formation induced by TP508 at
doses of 100 wg and 200 ug compared with untreated
controls. Based on these results, novel methods of stimu-
lating bone growth in a subject and novel implantable
pharmaceutical compositions are disclosed herein.
One embodimentof the present invention is a method of
stimulating bone growth at a site in a subject in need of
osteoinduction. The method comprises the step of adminis-
tering a therapeutically effective amountof an agonist ofthe
non-proteolytically activated thrombin receptorto thesite.
Another embodimentof the present invention is a phar-
maceutical composition comprising an implantable, bio-
compatible carrier and an agonist of the non-proteolytically
activated thrombin receptor.
The method of the present invention is directed at stimu-
lating bone growth in a subject and can be used atsites
where bone growth would not occur, absent treatment with
autologous bone grafts or administration of bone growth
factors. The method involves the administration of agonists
of the non-proteolytic thrombin receptor. Such agonists
include small peptides and physiologically functional
equivalents having homologyto the segment between amino
acid 508 and 530 of human prothrombin. These small
peptides are inexpensive to prepare in bulk quantities and
are osteoinductive at low dose. In addition, their lyophilized
form is stable for at least thirty months whenstored at 5° C.
and at 60% relative humidity.
DETAILED DESCRIPTION OF THE
INVENTION
“Osteoinduction” refers to stimulating bone growth at a
site within a subject at whichlittle or no bone growth would
occur if the site were left untreated. Sites which could
therapeutically benefit from the induction of bone growth
are referred to as “in need of osteoinduction”. Examples
include non-union fractures or other severe or massive bone
trauma.It is noted that bone growth normally occurs at bone
injuries such as simple or hairline fractures and well
opposed complex fractures with minimal gaps without the
need for further treatment. Such injuries are not considered
to be “in need of osteoinduction”.
Simple fracture repair appears to be quite different from
the induction of bone formation required to fill non-union
fractures, segmental gaps or bone voids caused, for example,
by removal of a bone tumor or cyst. These cases require
bone grafting or induction of new bone growth generally
employing some type of matrix or scaffolding to serve as a
bone growth substitute. Induced bone growth can also be
therapeutically beneficial at certain sites within a subject
(referred to as “ectopic” sites) where bone tissue would not
normally be found, such as asite in need of a bonegraft or
bone fusion. Fusions are commonly usedto treat lower back
pain by physically coupling one or more vertebrae to its
neighbor. The bone created by such a fusion is located at a
site not normally occupied by bonetissue. Osteoinduction at
these ectopic sites can act as a “graft substitute” whereby
induced bone growth between the vertebrae takes the place
of a graft and obviates the need for a second operation to
harvest bone for the grafting procedure. Induction of bone
growth is also needed for treating acquired and congenital
craniofacial and other skeletal or dental anomalies (see e.g.,
Glowacki et al., Lancet 1: 959 (1981)); performing dental
and periodontal reconstructions where lost bone replace-
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mentor bone augmentation is required suchas in a jaw bone;
and supplementing alveolar bone loss resulting from peri-
odontal disease to delay or prevent tooth loss (see e.g.,
Sigurdsson et al., J. Periodontol., 66: 511(1995)).
Applicants have discovered that compounds whichstimu-
late or activate the non-proteolytically activated thrombin
receptor (hereinafter “NPAR”) are osteoinductive. Such
compounds are said to be NPAR agonists. NPAR is a
high-affinity thrombin receptor present on the surface of
most cells. This NPAR componentis largely responsible for
high-affinity binding of thrombin, proteolytically inactivated
thrombin, and thrombin derived peptides to cells. NPAR
appears to mediate a number of cellular signals that are
initiated by thrombin independentofits proteolytic activity.
An example of one such signal is the upregulation of
annexin V and other molecules identified by subtractive
hybridization (see Sower, et. al., Experimental Cell
Research 247:422 (1999)). NPAR is therefore characterized
by its high affinity interaction with thrombin at cell surfaces
and its activation by proteolytically inactive derivatives of
thrombin and thrombin derived peptide agonists as
described below. NPAR activation can be assayed based on
the ability of molecules to stimulate cell proliferation when
added to fibroblasts in the presence of submitogenic con-
centrations of thrombin or molecules that activate protein
kinase C or compete with **°I-thrombin for high affinity
binding to thrombin receptors, as disclosed in U.S. Pat. Nos.
5,352,664 and 5,500,412 and in Glenn et al., J. Peptide
Research 1:65 (1988). NPAR is to be distinguished from
other thrombin binding proteins and the cloned family of
proteolytically-activated receptors for thrombin, including
the receptors PAR1, PAR2, PAR3 and PAR4. PAR1 pos-
sesses a specific thrombin cleavagesite that allows thrombin
cleavage to expose a new amino-terminus domain that acts
as a tethered ligand folding back onto itself inducing its
activation (see, Vu,et al., Cell. 64:1057 (1991)). PAR2 has
a similar mechanism for activation, but is principally acti-
vated by trypsin-like enzymes (see, Zhong, et al., J. Biol.
Chem. 267:16975 (1992)). PAR3 also has a similar mecha-
nism of activation and appears to function as a second
thrombin receptor in platelets (see, Ishihara, et al., Nature.
386:502 (1997)). PAR4 has been detected in mouse mega-
karyocytes and studies suggest that it also functions in
humanplatelets (see, Kahn,et al., Nature 394:690 (1998)).
In contrast with these PAR receptors, activation of NPAR
requires no proteolytic cleavage.
Several lines of evidence indicate that NPAR is distinct
from PAR receptors: (1) a population of cells has been
isolated that express fully functional PAR1 receptors, but are
non-responsive to thrombin due to a defect in the NPAR
signal transduction pathway (see, Kim, et al. J. Cell.
Physiol. 160:573 (1994)); (2) neutrophils bind?**I thrombin
with high affinity and their chemotaxis is stimulated by
proteolytically inactivated thrombin or NPAR agonists(see,
Ramakrishnan and Cammey, Mol. Biol. Cell 4:1993 (1993)),
yet they do not express PAR1(see Jenkins,etal., J. Cell Sci.
108:3059 (1995)); (3) IIC9 fibroblasts over-express PAR1,
but do not bind thrombin with high affinity (see, Kim, D.
Ph.D. Dissertation. The University of Texas Medical Branch
at Galveston, 1995; and Low,et al., “Cancer Cells 3/Growth
Factors and Transformation”, Cold Spring Harbor
Laboratory, New York); and (4) NPAR agonists havedistinct
effects on gene expression from those of the PAR receptor
agonist peptides (see, Sower, et. al., Experimental Cell
Research 247: 422 (1999).
One example of an NPAR agonist is a thrombin peptide
derivative, i.e., a polypeptide with no more than about fifty
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amino acids, preferably no more than about thirty amino
acids and having sufficient homology to the fragment of
human thrombin corresponding to prothrombin amino acids
508-530 (SEQ ID NO. 5) that the polypeptide activates
NPAR. The thrombin peptide derivatives described herein
preferably have between about 12 and 23 amino acids, more
preferably between about 19 and 23 amino acids. One
example of a thrombin peptide derivative comprises a moi-
ety represented by Structural Formula(I):
Asp-Ala-R a)
R is a serine esterase conserved domain. Serine esterases,
e.g., trypsin, thrombin chymotrypsin and the like, have a
region that is highly conserved. “Serine esterase conserved
domain” refers to a polypeptide having the amino acid
sequence of one of these conserved regionsoris sufficiently
homologousto one of these conserved regions such that the
thrombin peptide derivative retains NPAR activating ability.
A physiologically functional equivalent of a thrombin
peptide derivative encompasses molecules which differ from
thrombin derivatives in particulars which do not affect the
function of the thrombin receptor binding domain or the
serine esterase conserved amino acid sequence. Such par-
ticulars may include, but are not limited to, conservative
amino acid substitutions and modifications, for example,
amidation of the carboxyl terminus, acetylation of the amino
terminus, conjugation of the polypeptide to a physiologi-
cally inert carrier molecule, or sequencealterations in accor-
dance with the serine esterase conserved sequences.
A thrombin receptor binding domain is defined as a
polypeptide which directly binds to the thrombin receptor
and/or competitively inhibits binding between high-affinity
thrombin receptors and alpha thrombin. In one embodiment,
the serine esterase conserved sequence has the amino acid
sequence of SEQ ID NO.1 (Cys-Glu-Gly-Asp-Ser-Gly-Gly-
Pro-Phe-Val) or a C-terminal truncated fragment of a
polypeptide having the amino acid sequence of SEQ ID NO
1. It is understood, however, that zero, one, two or three
amino acids in the serine esterase conserved sequence can
differ from the corresponding amino acid in SEQ ID NO 1.
Preferably, the amino acids in the serine esterase conserved
sequence which differ from the corresponding aminoacid in
SEQ ID NO 1 are conservative substitutions, and are more
preferably highly conservative susbstitutions. A “C-terminal
truncated fragment” refers to a fragment remaining after
removing an amino acid or block of amino acids from the
C-terminus, said fragment having at least six and more
preferably at least nine amino acids.
More preferably, the serine esterase conserved sequence
has the amino acid sequence of SEQ ID NO 2 (Cys-X,-
Gly-Asp-Ser-Gly-Gly-Pro-X,-Val; X, is Glu or Gln and X,
is Phe, Met, Leu, His or Val) or a C-terminal truncated
fragment thereof having at least six amino acids, preferably
at least nine amino acids.
In a preferred embodiment, the thrombin peptide deriva-
tive comprises a serine esterase conserved sequence and a
polypeptide having a more specific thrombin amino acid
sequence Arg-Gly-Asp-Ala (SEQ ID NO 3). The Asp-Ala of
the thrombin receptor binding domain comprisethe first two
aminoacids of the serine esterase conserved sequence. One
example of a thrombin peptide derivative of this type
comprises Arg-Gly-Asp-Ala-Cys-X,-Gly-Asp-Ser-Gly-
Gly-Pro-X,-Val (SEQ ID NO 4). X, and X, are as defined
above. When the thrombin peptide derivative comprises
SEQ ID NO4,it preferably has the amino acid sequence of
SEQ ID NO 5 (Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-
Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-
US 6,894,027 B2
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Val) or an N-terminal truncated fragment thereof, provided
that zero, one, two or three amino acids at positions 1-9 in
the thrombin peptide derivative differ from the amino acid at
the corresponding position of SEQ ID NO 5.Preferably, the
amino acids in the thrombin peptide derivative which differ
from the corresponding amino acid in SEQ ID NO 5are
conservative substitutions, and are more preferably highly
conservative susbstitutions. An “N-terminal truncated frag-
ment’refers to a fragment remaining after removing an
amino acid or block of amino acids from the N-terminus,
preferably a block of no more than six amino acids, more
preferably a block of no more than three amino acids. A
physiologically functional equivalent of SEQ ID NO: 5 is
SEQ ID NO:6 which has the identical amino sequence of
SEQ ID NO:5 and also contains a C-terminal amide.
TP508is an example of a thrombin peptide derivative and
has the amino acid sequence of SEQ ID NO 5.
A “conservative substitution” is the replacement of an
amino acid with another amino acid that has the same net
electronic charge and approximately the same size and
shape. Amino acids with aliphatic or substituted aliphatic
amino acid side chains have approximately the same size
whenthe total number carbon and heteroatoms intheir side
chains differs by no more than about four. They have
approximately the same shape when the numberof branches
in the their side chains differs by no more than one. Amino
acids with phenyl or substituted phenyl groups in their side
chains are considered to have about the samesize and shape.
Listed below are five groups of amino acids. Replacing an
amino acid in a polypeptide with another amino acid from
the same group results in a conservative substitution:
Group I: glycine, alanine, valine, leucine, isoleucine,
serine, threonine, cysteine, and non-naturally occurring
amino acids with C1—C4 aliphatic or C1-C4 hydroxyl
substituted aliphatic side chains (straight chained or
monobranched).
Group II: glutamic acid, aspartic acid and non-naturally
occurring amino acids with carboxylic acid substituted
C1-C4 aliphatic side chains (unbranched or one branch
point).
Group III: lysine, ornithine, arginine and non-naturally
occurring amino acids with amine or guanidino substi-
tuted C1—C4 aliphatic side chains (unbranched or one
branch point).
Group IV: glutamine, asparagine and non-naturally occur-
ring amino acids with amide substituted C1-C4 ali-
phatic side chains (unbranched or one branch point).
Group V: phenylalanine, phenylglycine, tyrosine and
tryptophan.
A“highly conservative substitution”is the replacement of
an amino acid with another amino acid that has the same
functional group in the side chain and nearly the same size
and shape. Amino acids with aliphatic or substituted ali-
phatic amino acid side chains have nearly the same size
whenthe total number carbon and heteroatoms intheir side
chains differs by no more than two. They have nearly the
same shape when they have the same numberof branchesin
the their side chains. Example of highly conservative sub-
stitutions include valine for leucine, threonine for serine,
aspartic acid for glutamic acid and phenylglycine for phe-
nylalanine. Examples of substitutions which are not highly
conservative include alanine for valine, alanine for serine
and aspartic acid for serine.
Other NPAR agonists include small organic molecules
which bind and activate NPAR. Agonists of this type can be
conveniently identified with high through-put screening,
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6
e.g., with assays that assess the ability of molecules to
stimulate cell proliferation when added to fibroblasts in the
presence of submitogenic concentrations of thrombin or
molecules that activate protein kinase C as disclosed in U.S.
Pat. Nos. 5,352,664 and 5,500,412. The entire teachings for
USS. Pat. Nos. 5,352,664 and 5,500,412 are incorporated
herein by reference.
The term “NPAR agonist” also includes compounds and
combinations of compounds known to activate NPAR.
Examples are disclosed in U.S. Pat. Nos. 5,352,664 and
5,500,412 and include the combination of DIP-alpha-
thrombin with phorbol myristate acetate.
An implantable biocompatible carrier for use in the phar-
maceutical compositions described herein functions as a
suitable delivery or support system for the NPAR agonist. A
biocompatible carrier should be non-toxic, non-
inflammatory, non-immunogenic and devoid of other undes-
ired reactions at the implantation site. Suitable carriers also
provide for release of the active ingredient and preferably
for a slow, sustained release over time at the implantation
site.
Suitable carriers include porous matrices into which bone
progenitor cells may migrate. Osteogenic cells can often
attach to such porous matrices, which can then serve as a
scaffolding for bone and tissue growth. For certain
applications, the carrier should have sufficient mechanical
strength to maintain its three dimensional structure and help
support the immobilization of the bone segments being
united or grafted together. Porous matrices which provide
scaffolding for tissue growth can accelerate the rate of bone
growth andare said to be “osteoconductive”. Osteoconduc-
tive carriers are highly preferred for use in the pharmaceu-
tical compositions described herein.
Examples of suitable osteoconductive carriers include
collagen (e.g., bovine dermal collagen), fibrin, calcium
phosphate ceramics (e.g., hydroxyapatite and tricalcium
phosphate), calcium sulfate, guanidine-extracted allogenic
bone and combinations thereof. A numberofsuitable carri-
ers are commercially available, such as COLLOGRAFT
(Collagen Corporation, Palo Alto, Calif.), which is a mixture
of hydroxyapatite, tricalcium phosphate and fibrillar
collagen, and INTERPORE(Interpore International, Irvine
Calif.), which is a hydroxyapatite biomatrix formed by the
conversion of marine coral calcium carbonate to crystalline
hydroxyapatite.
A numberof synthetic biodegradable polymers can serve
as osteoconductive carriers with sustained release charac-
teristics. Descriptions of these polymers can be found in
Behravesh et al., Clinical Orthopaedics 367:S118 (1999)
and Lichun et al., Polymeric Delivery Vehicles for Bone
Growth Factors in “Controlled Drug Delivery-Designing
Technologies for the Future” Park and Mrsny eds., American
Chemical Society, Washington, D.C. (2000). The entire
teachings of these references are incorporated herein by
reference. Examples of these polymers include poly
a-hydroxy esters such as polylactic acid/polyglycolic acid
homopolymers and copolymers, polyphosphazenes
(PPHOS), polyanhydrides and poly(propylene fumarates).
Polylactic acid/polyglycolic acid (PLGA) homo and
copolymers are well knownin the art as sustained release
vehicles. The rate of release can be adjusted by the skilled
artisan by variation of polylactic acid to polyglycolic acid
ratio and the molecular weight of the polymer (see
Anderson, et al., Adv. Drug Deliv. Rev. 28:5 (1997), the
entire teachings of which are incorporated herein by
reference). The incorporation of poly(ethylene glycol) into
the polymeras a blend to form microparticle carriers allows
US 6,894,027 B2
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further alteration of the release profile of the active ingre-
dient (see Cleek et al., J. Control Release 48:259 (1997),the
entire teachings of which are incorporated herein by
reference). Ceramics such as calcium phosphate and
hyroxyapatite can also be incorporated into the formulation
to improve mechanical qualities.
PPHOSpolymers contain alternating nitrogen and phos-
phorous with no carbon in the polymer backbone, as shown
below in Structural Formula (ID):
()
The properties of the polymer can be adjusted by suitable
variation of side groups R and R' that are bonded to the
polymer backbone. For example, the degradation of and
drug release by PPHOS can be controlled by varying the
amount of hydrolytically unstable side groups. With greater
incorporation of either imidazolyl or ethylglycol substituted
PPHOS, for example, an increase in degradation rate is
observed (see Laurencinet al., J. Biomed Mater. Res. 27:963
(1993),the entire teachings of which are incorporated herein
by reference), thereby increasing the rate of drug release.
Polyanhydrides, shown in Structural Formula (IID, have
well defined degradation and release characteristics that can
be controlled by including varying amounts of hydrophobic
or hydrophilic monomers such as sebacic acid and 1,3-bis
(p-carboxyphenoxy)propane (see Leong et al., J. Biomed.
Mater. Res. 19:941 (1985),the entire teachings of which are
incorporated herein by reference). To improve mechanical
strength, anhydrides are often copolymerized with imides to
form polyanhydride-co-imides. Examples of polyanhydride-
co-imides that are suitable for orthopaedic applications are
poly(trimellitylimido-glycine-co-1,6-bis(carboxyphenoxy)
hexane and pyromellityimidoalanine: 1,6-bis(p-
carboxyphenoxy)hexane copolymers.
9 9I IO—C—R—C
Poly(propylene fumarates) (PPF) are highly desirable
biocompatible implantable carriers because they are an
injectable, in situ polymerizable, biodegradable material.
“Injectable” means that the material can be injected by
syringe through a standard needle used for injecting pastes
and gels. PPF, combined with a vinyl monomer (N-vinyl
pyrrolidinone) and aninitiator (benzoyl peroxide), forms an
injectable solution that can be polymerized in situ. It is
particularly suited for filling skeletal defects of a wide
variety of sizes and shapes (see Suggs et al., Macromol-
ecules 30:4318 (1997), Peter et al., J. Biomater. Sci. Poly,.
Ed. 10:363 (1999) and Yaszemski et al., Tissue Eng. 1:41
(1995), the entire teachings of which are incorporated herein
by reference). The addition of solid phase components such
as B-tricalctum phosphate and sodium chloride can improve
the mechanical properties of PPF polymers (see Peter et al.,
J. Biomed. Mater. Res. 44:314 (1999),the entire teachings of
which are incorporated herein by reference).
The pharmaceutical compositions of the present invention
can be administered by implantation at a site in need of
osteoinduction. “Implantation” or “administration at a site”
(It)
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meansin sufficient proximity to the site in need of treatment
so that osteoinduction occurs (e.g., bone growth in the
presence of the NPAR agonist butlittle or no growth in its
absence) at the site when the NPAR agonistis released from
the pharmaceutical composition.
The pharmaceutical compositions can be shaped as
desired in anticipation of surgery or shaped by the physician
or technician during surgery. It is preferred to shape the
matrix to span a tissue defect and to take the desired form of
the new tissue. In the case of bone repair of a non-union
defect, for example, it is desirable to use dimensions that
span the non-union. In bone formation procedures, the
material is slowly absorbed by the body and is replaced by
bonein the shape of or very nearly the shape of the implant.
Alternatively, the pharmaceutical compositions can be
administered to the site in the form of microparticles or
microspheres. The microparticles are placed in contact or in
close proximity to the site in need of osteoinduction either
by surgically exposing the site and applying the micropar-
ticles on or in close proximity to the site by painting,
pipetting, spraying, injecting or the like. Microparticles can
also be delivered to the site by endoscopy or by laparoscopy.
The preparation of PLGA microparticles and their use to
stimulate bone growth are described in Examples 1 and 2.
In yet anotheralternative, the pharmaceutical composition
can be partially enclosed in a supporting physical structure
such as a mesh, wire matrix, stainless steel cage, threaded
interbody fusion cage and the like before administering to
the site in need of osteoinduction.
Anotheralternative for applying the pharmaceutical com-
position of the present invention is by injection. Composi-
tions which are injectable include the solutions of poly
(propylene fumarate) copolymers described above and
pastes of calcium phosphate ceramics (see Schmitz et al., J.
Oral Maxillofacial Surgery 57:1122 (1999), the entire teach-
ings of which are incorporated herein by reference). Inject-
able compositions can be injected directly to the site in need
of osteoinduction and can conveniently be used to fill voids
and fuse bones without the need for invasive surgery.
NPAR agonists can also be administered by means other
than implantation, for example, by applying a solution
comprising the NPAR agonist in an acceptable pharmaceu-
tical carrier directly to or in near proximity to the site.
Administration of a solution can be conveniently
accomplished, for example, by syringe, either through a
surgical opening or by parenteral administration to the
desired site. Standard pharmaceutical formulation tech-
niques may be employed such as those described in Rem-
ington’s Pharmaceutical Sciences, Mack Publishing
Company, Easton, Pa. Suitable pharmaceutical carriers for
parenteral administration include, for example, sterile water,
physiological saline, bacteriostatic saline (saline containing
about 0.9% mg/ml benzyl alcohol), phosphate-buffered
saline, Hank’s solution, Ringer’s-lactate and the like.
A “therapeutically effective amount” is the quantity of
NPAR agonist which results in bone growth wherelittle or
no bone growth would occur in the absence of the agonist.
Typically, the agonist is administered for a sufficient period
oftime to achieve the desired therapeutic or cosmetic effect,
1e., sufficient bone growth. The amount administered will
depend on the amount of bone growth that is desired, the
health, size, weight, age and sex of the subject and the
release characteristics of the pharmaceutical formulation.
Typically, between about 1 ug per day and about 1 mg per
day of NPAR agonist(preferably between about 5 ug per day
and about 100 wg per day) is administered by continuous
release or by direct application to the site in need of bone
growth.
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A NPAR agonist or an implantable pharmaceutical com-
position of the present invention can be used in conjuction
with an implantable prosthetic device. For example, a thera-
peutically effective amount of the pharmaceutical composi-
tion can be disposed on the prosthetic implant on a surface
region that is implantable adjacent to a site in need of
osteoinduction. Alternatively, the prosthetic device is con-
structed so as to continuously release the implantable phar-
maceutical composition or NPAR agonist at a pre-
determined rate. The prosthesis may be made from a
material comprising metal or ceramic. Examples of pros-
thetic devices include a hip device, a screw, a rod and a
titanium cage for spine fusion.
Thusthis invention also provides a methodfor stimulating
bone growth by implanting a prosthetic device into a site in
need of osteoinduction in a subject. The prosthetic is at least
partially coated with an implantable pharmaceutical com-
position described hereinabove and implanted at a site in
need of osteoinduction and maintained atthe site for a period
of time sufficient to permit stimulation of bone growth.
A “subject” is preferably a human, but can also be an
animal in need of treatment, e.g., companion animals (e.g.,
dogs, cats, and the like), farm animals (e.g., cows, pigs,
horses and the like) and laboratory animals (e.g., rats, mice,
guinea pigs and the like).
Thrombin peptide derivatives can be synthesized by solid
phase peptide synthesis (e.g., BOC or FMOC) method, by
solution phase synthesis, or by other suitable techniques
including combinations of the foregoing methods. The BOC
and FMOC methods, whichare established and widely used,
are described in Merrifield, J. Am. Chem. Soc. 88:2149
(1963); Meienhofer, Hormonal Proteins and Peptides, C. H.
Li, Ed., Academic Press, 1983, pp. 48-267; and Barany and
Merrifield, in The Peptides, E. Gross and J. Meienhofer,
Eds., Academic Press, New York, 1980, pp. 3-285. Methods
of solid phase peptide synthesis are described in Merrifield,
R. B., Science, 232: 341 (1986); Carpino, L. A. and Han, G.
Y., J. Org. Chem., 37: 3404 (1972); and Gauspohl,H.etal.,
Synthesis, 5: 315 (1992)). The teachings ofthese six articles
are incorporated herein by reference in their entirety.
The invention is illustrated by the following examples
which are not intended to be limiting in any way.
EXEMPLIFICATION
Example 1
Preparation of Polylactic Acid/Polyglycolic Acid
Copolymer Microspheres of TP508
A double emulsion technique was used to prepare micro-
spheres of polylactic acid/polyglycolic acid copolymer
(PLGA)containing TP508. Briefly, the matrix components
were dissolved in methylene chloride and TP508 was dis-
solved in water. The two were gradually mixed together
while vortexing to form a water-in-oil (W/O) emulsion.
Polyvinyl alcohol (0.3% in water) was added to the emulsion
with further vortexing to form the second emulsion (O/W),
thereby forming a double emulsion: an O/W emulsion
comprised of PLGA droplets, and within those droplets, a
second disperse phase consisting of TP508 in water. Upon
phase separation, the PLGA droplets formed discrete micro-
spheres containing cavities holding TP508. To cause phase
separation of the microspheres, a 2% isopropyl alcohol
solution was added. The particles were collected by
centrifugation, and then lyophilized to remove residual
moisture. The composition of the matrix was varied to form
microspheres with different release kinetics (Table 1).
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TABLE1
 
Composition of different microsphere formulations
% poly-
Formu- Polymer % ethylene
lation PLGA M.Wt. TP508 glycol
A 50:50 46,700 5 0)
B 50:50 7,200 5 0)
Cc 50:50 46,700 5 5
D 50:50 46,700 5 0)
E 75:25 120,000 5 0)
 
The mean diameter of the micro spheres was measured in
a Coulter counter and the drug entrapment efficiency was
measured by spectrophotometric assay at 276 nm following
dissolution of a weighed sample of micro spheres in meth-
ylene chloride and extraction of the released drug into water
(Table 2).
TABLE 2
 
Formulation diameter and drug entrapment efficiency
Formulation Diameter, wm TP508 Entrapment, %
A 26.0 53.8
B 16.2 27.1
Cc 17.6 58.9
D 23.9 42.6
E 25.8 36.2
 
To measure TP508 release from the different PLGA
matrices, 20 mg of microspheres were placed in 1.0 ml of
PBS contained in 1.5 ml polypropylene microcentrifuge
tubes. Tubes were incubated at 37° C. and shaken at 60 rpm.
Atvarious times, the tubes were centrifuged and the super-
natant containing released TP508 was removed and frozen
for subsequent analysis. Fresh PBS wasaddedto the micro-
spheres and incubation was continued. TP508 in the super-
natant was measured by absorbance at 276 nm. For each
formulation, quadruplicate release determinations were per-
formed. Formulations B and D showed nodetectable drug
release during 28 days of incubation at 37° C. The remaining
formulations all released detectable amounts of TP508,
although in all cases the amountof drug released fell below
detectable limits (<1 “g/mg matrix/day) within 3-4 days.
Formulations A and C showedthe greatest release of TP508,
releasing 60-80% of the entrapped drug over 3-4 days. The
formulation with the fastest release kinetics, C, was chosen
for further testing in in vivo studies. Example 2
PLGAMicrospheres Containing TP508 Induce
Bone Formation in Large (1.5 cm) Defects in
Rabbit Ulna
A1.5 cm segmental defect was created in each ulna of 20
male New Zealand rabbits. Thesebilateral ulnar osteotomies
were created exactly the same size by using a small metal
guide to direct the cutting blade of the oscillating microsaw.
Each rabbit acted as its own control; thus the left defect was
filled with microspheres that did not contain TP508, while
the right defect wasfilled with microspheres containing 100
or 200 ug TP508 (10 animals/group). The microspheres
were prepared as described in Example 1. Rabbits given
bilateral ulnar osteotomies were randomly divided into two
groups. The first group received 100 ug of TP508 in micro-
spheres (30 mg) in the right limb and microspheres alone in
the left limb. The second group wastreated similarly, but
US 6,894,027 B2
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received 200 ug of TP508. These different doses were
achieved by mixing TP508-containing and TP508-devoid
microspheresin different proportions. Animals were x-rayed
at two week intervals, beginning at week three, and sacri-
ficed at nine weeks.
100 ug of TP508 stimulated mineralization in the defect
at 3 and 5 weeks post-surgery. X-rays at 7 and 9 weeks
appeared similar to those obtained at 5 weeks. Animals were
sacrificed at 9 weeks post-surgery and the ulna-radius was
removed and photographed. In most cases a large defect is
still visible in ulnas from the control limbs, in contrast with
the TP508-treated limbs, in which most of the defects have
successfully closed.
After sacrifice at 9 weeks post-surgery, repair strength
was measured by torsion testing (MTS-858 Minibionix
machine). The results are shown in Tables 3 and 4.
TABLE 3
 
Torsion testing of segmental defects treated with 100 ug TP508.
 
Parameter Control SEM TP508, 100 xg SEM
Ultimate torque 0.107 0.034 0.255+ 0.041
Failure torque 0.103 0.032 0.239+ 0.042
Ultimate energy 0.815 0.365 1.916 0.398
Failure energy 0.940 0.436 2.064 0.421
Stiffness coeff. 0.013 0.004 0.028 0.006
7) < 0.05,
+p < 0.01
TABLE 4
Torsion testing of segmental defects treated with 200 ug TP508.
 
Parameter Control SEM TP508, 200 pg SEM
Ultimate torque 0.095 0.042 0.322* 0.046
Failure torque 0.093 0.041 0.306* 0.046
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TABLE 4-continued
 
Torsion testing of segmental defects treated with 200 ug TP508.
Parameter Control SEM TP508, 200 pg SEM
Ultimate energy 0.534 0.355 2.947* 0.543
Failure energy 0.641 0.374 3.433* 0.701
Stiffness coeff. 0.016 0.006 0.033 0.004
*p < 0.05,
*p < 0.005
At 100 xg, TP508 more than doubled the mechanical
strength of the healing defect as measured byall the param-
eters tested (Table 3). Even stronger repairs were noted in
the 200-ug group (Table 4), with most parameters being
approximately 50% higher than those seen in the low dose
treatment group.
In summation, ulnar osteotomies treated with micro-
spheres containing the NPAR agonist TP508 showed evi-
dence of bone mineralization and growth whereas in most
control osteotomies that received osteoconductive
microspheres, there was no bone growth and/orfailureto fill
the voided region. Mechanical testing for mechanical
strength and stiffness confirmedsignificant effects of TP508
on bone formation in this model. Because TP508 induced
bone formation in sites where it did not occur without
TP508, this discovery of osteoinduction is distinct from
prior studies, in which TP508 accelerated the rate of normal
fracture healing in fracture or small gap defects that would
heal without TP508.
While this invention has been particularly shown and
described with references to preferred embodimentsthereof,
it will be understood by those skilled in the art that various
changes in form and details may be made therein without
departing from the scope of the invention encompassed by
the appended claims.
SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 7
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 1
LENGTH: 10
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE :
<400> SEQUENCE: 1
Cys Glu Gly Asp Ser Gly Gly Pro Phe Val
OTHER INFORMATION: fragment of human prothrombin
1 5 10
<210> SEQ ID NO 2
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: fragment of human prothrombin
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (2)...(2)
<223> OTHER INFORMATION: Xaa = Glu or Gln
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (9)... (9)
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<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<400> SEQUENCE: 2
Cys Xaa Gly Asp Ser Gly Gly Pro Xaa Val
1 5 10
<210> SEQ ID NO 3
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: fragment of human prothrombin
<400> SEQUENCE: 3
Arg Gly Asp Ala
1
<210> SEQ ID NO 4
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: fragment of human prothrombin
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (6)...(6)
<223> OTHER INFORMATION: Xaa = Glu or Gln
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (13)...(13)
<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<400> SEQUENCE: 4
Arg Gly Asp Ala Cys Xaa Gly Asp Ser Gly Gly Pro Xaa Val
1 5 10
<210> SEQ ID NO 5
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: fragment of human prothrombin
<400> SEQUENCE: 5
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val
20
<210> SEQ ID NO 6
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: c-terminal amidated fragment of human thrombin
<220> FEATURE:
<221> NAME/KEY: AMIDATION
<222> LOCATION: (23)...(23)
<223> OTHER INFORMATION: valine is amidated
<400> SEQUENCE: 6
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val
20
<210> SEQ ID NO 7
<211> LENGTH: 23
<212> TYPE: PRT
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<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: c-terminal amidated fragment of human thrombin
<220> FEATURE:
<221> NAME/KEY: AMIDATION<222> LOCATION: (23)...(23)
<223> OTHER INFORMATION: valine is amidated as NH2
<400> SEQUENCE: 7
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys
1 5 10
Asp Ser Gly Gly Pro Phe Val
20
Glu Gly
15
Whatis claimedis:
1. A method of stimulating bone growth in a subject at a
site in need of bone growth and at which bone growth would
not occur if left untreated, said method comprising the step
of administering to the site a therapeutically effective
amount of the peptide Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-
Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-
Phe-Val-NH, (SEQ ID NO:7).
2. The method of claim 1 wherein the agonist is admin-
istered in a pharmaceutical composition additionally com-
prising an implantable, biocompatible carrier.
3. The method of claim 2 wherein the implantable,
biocompatible carrier is an osteoconductive matrix.
4. The method of claim 1 wherein the carrier comprises a
polylactic acid/polyglycolic acid homopolymer or copoly-
mer.
20
25
30
5. A method of stimulating bone growth in a subject at a
site in need of a bone graft, said method comprising the step
of administering to the site a therapeutically effective
amount of the peptide Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-
Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-
Phe-Val-NH, (SEQ ID NO:7).
6. A method of stimulating bone growth in a subject at a
segmental bone gap, a bone void or a non-union fracture
comprising the step of administering to the bone gap, bone
void or non-union fracture a therapeutically effective
amount of the peptide Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-
Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-
Phe-Val-NH, (SEQ ID NO:7).
